Updated YJUVEK Label and KB803 Progress Could Be A Game Changer For Krystal Biotech (KRYS) [Yahoo! Finance]
Krystal Biotech, Inc. (KRYS)
Last krystal biotech, inc. earnings: 11/4 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.krystalbio.com/investors
Company Research
Source: Yahoo! Finance
guidance for epidermolysis bullosa and reinforcing its role in this rare disease space. This label update, alongside progress on Krystal's pipeline candidate KB803, underscores how regulatory evolution and innovation may reshape the epidermolysis bullosa treatment landscape. We'll now examine how the updated FDA label for B-VEC/YJUVEK may influence Krystal Biotech's investment narrative and risk profile. This technology could replace computers: discover 24 stocks that are working to make quantum computing a reality Krystal Biotech Investment Narrative Recap To own Krystal Biotech, you need to believe VYJUVEK can sustain meaningful, though variable, rare disease revenue while the broader gene therapy pipeline matures into additional products. The updated FDA label for B-VEC/YJUVEK supports its clinical role in epidermolysis bullosa but does not materially change the near term focus on smoothing revenue “waviness” and reducing dependence on a single commercial asset as the key
Show less
Read more
Impact Snapshot
Event Time:
KRYS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KRYS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KRYS alerts
High impacting Krystal Biotech, Inc. news events
Weekly update
A roundup of the hottest topics
KRYS
News
- Epidermolysis Bullosa Market Set for Significant Upswing During the Forecast Period (2025-2034) Amid Rising Therapeutic Advancements | DelveInsight [Yahoo! Finance]Yahoo! Finance
- VYJUVEK (Krystal Biotech) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F [Yahoo! Finance]Yahoo! Finance
- Guggenheim Lifts PT on Krystal Biotech (KRYS) to $284 From $224 [Yahoo! Finance]Yahoo! Finance
- Krystal Biotech (KRYS) had its price target raised by Guggenheim from $224.00 to $284.00. They now have a "buy" rating on the stock.MarketBeat
- Krystal Biotech to Present at TD Cowen 46th Annual Health Care ConferenceGlobeNewswire
KRYS
Earnings
- 2/17/26 - Beat
KRYS
Sec Filings
- 3/6/26 - Form 3
- 3/6/26 - Form 3
- 3/6/26 - Form 4
- KRYS's page on the SEC website